Wedbush reissued their outperform rating on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research report report published on Wednesday morning, MarketBeat reports. The brokerage currently has a $11.00 price objective on the stock.
A number of other brokerages have also recently commented on IMUX. Aegis reduced their target price on Immunic from $40.00 to $35.00 and set a buy rating for the company in a report on Monday, August 8th. HC Wainwright reissued a buy rating and set a $26.00 target price on shares of Immunic in a report on Monday. Finally, SVB Leerink reduced their target price on Immunic from $45.00 to $9.00 and set an outperform rating for the company in a report on Friday, June 3rd. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $24.00.
Immunic Price Performance
Shares of Immunic stock opened at $3.34 on Wednesday. The business has a 50 day simple moving average of $4.37 and a two-hundred day simple moving average of $6.21. Immunic has a 12 month low of $2.52 and a 12 month high of $14.50. The stock has a market capitalization of $102.09 million, a P/E ratio of -1.10 and a beta of 1.98.
Institutional Investors Weigh In On Immunic
Immunic Company Profile
Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.
- Get a free copy of the StockNews.com research report on Immunic (IMUX)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- General Mills: Superior Returns With Less Volatility
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.